Havah Therapeutics Pty Ltd
HavaH Therapeutics is dedicated to developing therapies for breast cancer, focusing on early prevention and treatment with reduced side effects. Their innovative approach involves targeted hormonal modulation, particularly in treating ductal carcinoma in situ (DCIS), to reduce the need for invasive surgeries and improve patient outcomes. The company boasts an advanced clinical-stage product with significant clinical exposure and has been recognized in scientific publications like Nature Medicine.
Industries
Nr. of Employees
small (1-50)
Havah Therapeutics Pty Ltd
Patents
Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor with sustained multi-phasic release profiles and methods of use
US-12128055-B2
View DetailsPharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor with sustained multi-phasic release profiles and methods of use
US-11524014-B2
View DetailsReduction of side effects from aromatase inhibitors used for treating breast cancer
US-10765684-B2
View Details
Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor with sustained multi-phasic release profiles and methods of use
US-12128055-B2
View DetailsPharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor with sustained multi-phasic release profiles and methods of use
US-11524014-B2
View DetailsReduction of side effects from aromatase inhibitors used for treating breast cancer
US-10765684-B2
View DetailsProducts
Subcutaneous extended‑release combination hormone therapy pellet (testosterone + aromatase inhibitor)
A subcutaneous, extended‑release pellet formulation combining an androgen and an aromatase inhibitor designed to maintain intramammary DHT levels, modulate the breast hormonal environment, and reduce indicators of breast cancer risk.
Subcutaneous extended‑release combination hormone therapy pellet (testosterone + aromatase inhibitor)
A subcutaneous, extended‑release pellet formulation combining an androgen and an aromatase inhibitor designed to maintain intramammary DHT levels, modulate the breast hormonal environment, and reduce indicators of breast cancer risk.
Services
Support and conduct of clinical studies (open‑label cohorts and participation in multi‑site platform trials) to evaluate endocrine therapeutic approaches for prevention and early treatment.
Support and conduct of clinical studies (open‑label cohorts and participation in multi‑site platform trials) to evaluate endocrine therapeutic approaches for prevention and early treatment.
Expertise Areas
- Breast cancer prevention therapeutics
- Endocrine therapy development
- Drug delivery system development (subcutaneous implants)
- Clinical trial design and execution for early‑stage breast cancer/DCIS
Key Technologies
- Extended‑release subcutaneous implant drug delivery
- Combination endocrine therapy (androgen + aromatase inhibitor)
- Pharmacokinetic profiling
- Imaging biomarker analysis (mammographic density, BPE)
News & Updates
A webinar discussing new treatment approaches for DCIS, aiming to reduce unnecessary surgeries and revolutionize treatment.
Discussion on changing breast cancer treatment paradigms through collaboration on an I-SPY trial, focusing on DCIS.
A webinar discussing new treatment approaches for DCIS, aiming to reduce unnecessary surgeries and revolutionize treatment.
Discussion on changing breast cancer treatment paradigms through collaboration on an I-SPY trial, focusing on DCIS.